Beijing Business News (Reporter Ding Ning) On the evening of April 23,baccaratdinnerset, Puli Pharmaceutical (300630)(300630) issued an announcement sayingbaccaratdinnerset, the company recently received a Class 4 chemical marketing authorization for oseltamivir phosphate capsules issued by the State Food and Drug Administration.

Data show that oseltamivir phosphate is an influenza virus neuraminidase inhibitor and an ethyl ester prodrug that requires ester hydrolysis to be converted into the active form of oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase and affects the release of virus particles. It can be used for the treatment of influenza A and B in adults and children 1 year old and older (oseltamivir phosphate can effectively treat influenza A and B, but clinical application data on influenza B are not yet available), and patients should use it within 48 hours of the first symptoms. It can also be used for the prevention of influenza A and B in adults and young people aged 13 and over.